CN102662013A - Quantitative detection method of sarcosine in urine sample - Google Patents
Quantitative detection method of sarcosine in urine sample Download PDFInfo
- Publication number
- CN102662013A CN102662013A CN2012101545904A CN201210154590A CN102662013A CN 102662013 A CN102662013 A CN 102662013A CN 2012101545904 A CN2012101545904 A CN 2012101545904A CN 201210154590 A CN201210154590 A CN 201210154590A CN 102662013 A CN102662013 A CN 102662013A
- Authority
- CN
- China
- Prior art keywords
- methyl amimoacetic
- amimoacetic acid
- urine sample
- sarcosine
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to a quantitative detection method of sarcosine in a urine sample, belonging to the field of chemical quantitative analysis. The method comprises the following sequential steps: (1) diluting the urine sample with an organic solvent acetonitrile, adding internal standard working solution sarcosine-d3, carrying out mixing spinning and centrifuging, discarding the precipitates, sucking supernatant and mixing the supernatant with acetonitrile for analysis and test; (2) taking a silica bonded phase filler as an analytic column, adding formic acid and ammonium formate to a mobile phase acetonitrile aqueous solution to serve as modifying agents and ensuring sarcosine to be chromatographically separated from other interfering substances; (3) adopting an electrospray ionization tandem mass spectrometer to detect sarcosine in the positive ion detection mode; and (4) calculating the result: calculating the content of sarcosine in the urine sample with the obtained peak area or peak height according to the isotope internal standard dilution method. The method has the advantages of high specificity, sensitivity and accuracy and low cost, is simple and fast and is suitable for the requirement of quantitative detection of sarcosine in the mass low-cost clinical urine samples.
Description
Technical field
The invention belongs to the quantitative chemical analysis technical field, be specifically related to a kind of quantitative detecting method of methyl amimoacetic acid, relate in particular to the quantitative detecting method of methyl amimoacetic acid in a kind of urine sample.
Background technology
The screening diagnosis method thereof of prostate cancer mainly comprises serum prostate specific antigen mensuration (PSA), digital rectal examination, transrectal ultrasonography, prostata tissue aspiration biopsy etc. at present.The PSA examination is considered to the index of predicting that prostate cancer is best and widespread use clinically.But its specificity is limited, and some hyperplasia of prostate and prostatitis patient PSA also can raise, and the mistaken diagnosis situation happens occasionally.The aspiration biopsy of prostate systematicness is a diagnosing prostate cancer method the most reliably, belongs to the invasive inspection, need under the B ultrasonic guiding, carry out, and check result depends critically upon the accuracy of puncture position.What is more important, existing diagnostic method often make the clinical tumor doctor can diagnose out prostate cancer easily, and the biological characteristics that but can't judge cancer cell is aggressive or Non-Invasive, promptly judge the danger of cancer.And this might cause malignant prostate cancer patient to lose best therapy apparatus meeting.
Through micromolecule in the detection of biological sample or big molecular biosciences mark is the effective means of disorder in screening and diagnosis, has important value and clinical meaning for early diagnosis, treatment and the prognosis of disease.Therefore no matter from solving the angle of a clinical prostate cancer diagnosis and treatment difficult problem; Still from survival rate that improves the cancer patient and the angle that reduces the treatment cost; Seek the higher biomarker of specificity; Particularly can characterize the invasive biomarker of prostate cancer, all be the problem of needing solution clinically badly.
Methyl amimoacetic acid is the natural amino acid of a kind of human muscle of being present in and its hetero-organization, is the metabolic product of glycocoll.Research shows; Methyl amimoacetic acid content in the aggressive prostate cancer significantly raises; And can in urine sample, detect, 66 routine patients with prostate cancer and 200 routine normal healthy people urine methyl amimoacetic acid levels are respectively 404 ng/mL and 104 ng/mL, the obviously increase in cases for prostate cancer of methyl amimoacetic acid value (
p<0.001).Amass below experimenter's performance curve of methyl amimoacetic acid and methyl amimoacetic acidcreatinine ratio (ROC curve) in the urine sample and be respectively 0.904 and 0.946.The prompting methyl amimoacetic acid has very high check sensitivity and specificity.This makes methyl amimoacetic acid become candidate's biomarker of prostate cancer non-damage diagnosis, also might become new better prostate cancer diagnosis mark.Present detection for methyl amimoacetic acid; Adopt high performance liquid chromatography, gas chromatography-mass spectrography and LC/MS respectively; Major defect is a poor specificity, and what be difficult to realize methyl amimoacetic acid and interfering material separates the process method step more complicated of sample fully.
Summary of the invention
Technical matters to be solved by this invention provides the quantitative detecting method of methyl amimoacetic acid in a kind of urine sample, can be accurately the content of methyl amimoacetic acid in the detection by quantitative urine sample delicately.
For achieving the above object, the quantitative detecting method of methyl amimoacetic acid in a kind of urine sample provided by the invention is characterized in that:
(1) urine sample dilution in acetonitrile: get 100 μ L urine samples at random, adding 20 μ L concentration is mark working fluid in 50 μ g/mL methyl amimoacetic acid-d3, adds 200 μ L acetonitriles; DL 30s; Centrifugal 3 min of 15000 rpm abandon deposition, draw 100 μ L supernatants and mix with 300 μ L acetonitriles; Be transferred to the sample introduction bottle, supply analytical test;
(2) chromatographic resolution: with silica gel bonded phase filling is analytical column; With the WS is mobile phase A, and acetonitrile solution is a Mobile phase B, and said A contains 0.02～0.4% formic acid and 1～5mmol/L ammonium formate in mutually as modifier; Flow velocity is 0.1～1 mL/min; Isocratic elution or gradient elution with methyl amimoacetic acid wash-out from the analytical column, are realized chromatographic resolution with other interfering materials;
(3) Mass Spectrometer Method: adopt the electric spray ion source tandem mass spectrometer, under the positive ion detecting pattern, the multiple-reaction monitoring scanning analysis detects methyl amimoacetic acid;
(4) result calculates: with methyl amimoacetic acid peak area or the peak heights that Mass Spectrometer Method obtains, press the isotopic dilution internal standard method and calculate the content of methyl amimoacetic acid in urine sample.
Said step (3) Mass Spectrometer Method source parameters is set to methyl amimoacetic acid sense channel m/z 90/44, methyl amimoacetic acid-d3 sense channel m/z 93/47, and the ion channel scope is ± 0.5 m/z.
The content of methyl amimoacetic acid belongs to the non-damage detection method in the detection by quantitative urine sample of the present invention.Adopt dilution in acetonitrile to handle urine sample; With silica gel bonded phase filling post is analytical column, and moving phase adds formic acid and ammonium formate is a modifier, isocratic elution or gradient elution; Under positive ion mode; Measure with the multiple-reaction monitoring method,, press the isotopic dilution inner mark method ration and detect with peak area or the peak heights that the methyl amimoacetic acid Mass Spectrometer Method obtains.The present invention can realize that methyl amimoacetic acid separates and non-interference with the endogenous chaff interference fully, and the minimum quantitative limit of methyl amimoacetic acid can reach 100 ng/mL, and the precision of method (in relative standard deviation) is less than 12%, and accuracy is 87.8%-99.5%.The specificity of method, sensitivity, precision and accuracy are higher, and with low cost, simple fast, be applicable to clinically the requirement of methyl amimoacetic acid detection by quantitative in the urine sample low-costly and in high volume.
Description of drawings
The typical curve of Fig. 1 methyl amimoacetic acid;
With methyl amimoacetic acid concentration is the X axle, is the Y axle with methyl amimoacetic acid and interior mark peak area ratio, handles through the 1/X weight, and in concentration 100 ng/mL to 5000 ng/mL scopes, linearly dependent coefficient is 0.9998.
The chromatogram of methyl amimoacetic acid in Fig. 2 urine sample.
1-methyl amimoacetic acid chromatographic peak among the figure, 2-chaff interference chromatographic peak.Visible by diagram, the present invention can realize separating and non-interference fully of methyl amimoacetic acid 1 and chaff interference 2, has good chromatographic resolution ability.
Embodiment
Below in conjunction with embodiment the present invention is done further elaboration, be intended to explain the technical scheme that the present invention relates to, disclose most preferred embodiment of the present invention, those skilled in the art can be understood and embodiment of the present invention.But be to be understood that the present invention is not limited to the embodiment of publicity, based on enlightenment of the present invention, any conspicuous conversion or alternative also should be considered to fall into protection scope of the present invention.
Typical curve and Quality Control preparation: with the WS preparation of 20% acetonitrile, methyl amimoacetic acid typical curve concentration is 100,200,500,1000,2000,5000 ng/mL.With the WS preparation minimum quantitative concentrations of methyl amimoacetic acid (100 ng/mL) of 20% acetonitrile, low concentration (300 ng/mL), middle concentration (1200 ng/mL), the quality-control sample of high concentration (4000 ng/mL).Get 6 parts of urine samples in addition at random, as the actual urine sample of method detection.
The concentration of each material is concentration expressed in percentage by volume among the embodiment except that indicating especially.
Detect methyl amimoacetic acid concentration in the urine sample.
(1) urine sample dilution in acetonitrile: get 100 μ L urine samples at random, adding 20 μ L concentration is mark working fluid in 50 μ g/mL methyl amimoacetic acid-d3, adds 200 μ L acetonitriles; DL 30s; Centrifugal 3 min of 15000 rpm abandon deposition, draw 100 μ L supernatants and mix with 300 μ L acetonitriles; Be transferred to the sample introduction bottle, supply analytical test.
(2) chromatographic resolution: (Hypersil Thermo) is analytical column for 2.1 * 100mm, 5 μ m with silica gel bonded phase filling post; Mobile phase A is the WS that contains 0.02% formic acid and 1mmol/L ammonium formate, and Mobile phase B is an acetonitrile, mobile phase A: the volume ratio of Mobile phase B is 60%: 40%, and flow velocity is 0.3mL/min, isocratic elution, and sample size 5 μ L are with methyl amimoacetic acid wash-out from the analytical column.
(3) Mass Spectrometer Method: (API 4000 to adopt the electric spray ion source tandem mass spectrometer; American AB Sciex company), under the positive ion detecting pattern, the multiple-reaction monitoring scanning analysis; Methyl amimoacetic acid sense channel 90/44 (± 0.5 m/z), methyl amimoacetic acid-d3 sense channel 93/47 (± 0.5 m/z).Source parameters is set to: ionization voltage: 5000V; Ionization temperature: 550 ℃; Spraying gas: 60 psi; Heat air: 60 psi; Gas curtain gas: 25 psi; Collision gas: medium; Remove a bunch voltage: 21 V; Inlet voltage: 4 V; Impact energy: 20 V; Outlet voltage: 6 V.
(4) computing method do as a result, and the methyl amimoacetic acid peak area so that Mass Spectrometer Method obtains compares with typical curve, calculates the content of methyl amimoacetic acid in the urine sample by internal standard method.Setting up the typical curve of methyl amimoacetic acid, is the X axle with methyl amimoacetic acid concentration, is the Y axle with methyl amimoacetic acid and interior mark peak area ratio, handles through the 1/X weight, and in concentration 100 ng/mL to 5000 ng/mL scopes, linearly dependent coefficient is 0.9998 (Fig. 1).The detection method linear relationship that methyl amimoacetic acid in the urine sample provided by the invention is described is good.
The detection precision (in relative standard deviation) of methyl amimoacetic acid is 3.68%～10.5% in the quality-control sample, and accuracy is 92.6%～103.5%, explains that the present invention has precision quantitation capabilities accurately.
Get 6 parts of urine samples at random, be numbered 1,2,3,4,5,6, calculate through typical curve, urine methyl amimoacetic acid concentration is respectively 136,147,150,215,246,107 ng/mL, explains that the present invention can realize the mensuration of methyl amimoacetic acid in the urine sample.The chromatogram of methyl amimoacetic acid is seen Fig. 2 in the urine sample, and among the figure, 1 is the chromatographic peak of the methyl amimoacetic acid in the urine sample, and 2 is the chromatographic peak of chaff interference.The chromatographic retention of methyl amimoacetic acid is 5.88 min.By shown in Figure 2 visible, the present invention has good chromatographic resolution ability, can realize separating and non-interference fully of methyl amimoacetic acid 1 and chaff interference 2.
Mobile phase A changes the WS that contains modifier 0.1% formic acid and 1mmol/L ammonium formate into, and Mobile phase B is an acetonitrile, mobile phase A: the volume ratio of Mobile phase B is 60%: 40%; Isocratic elution, flow velocity changes 0.1mL/min into, sample size 5 μ L; Other is with embodiment 1 operation; Methyl amimoacetic acid concentration in 6 parts of urine samples of same mensuration is respectively 127,135,142,218,250,112 ng/mL, and is approaching with embodiment 1 mensuration result; The moving phase combination of adopting present embodiment is described, can be realized the accurate mensuration of methyl amimoacetic acid equally.
Embodiment 3
Adopt silica gel bonded phase filling post (4.6 * 150mm, 5 μ m, Hypersil; Thermo) be analytical column, mobile phase A changes the WS that contains modifier 0.4% formic acid and 5 mmol/L ammonium formates into, and Mobile phase B is an acetonitrile; Mobile phase A: the volume ratio of Mobile phase B is 60%: 40%; Isocratic elution, flow velocity change 1.0 mL/min into, sample size 10 μ L.The employing peak height method calculates; Other is with embodiment 1 operation; Methyl amimoacetic acid concentration in 6 parts of urine samples of same mensuration is respectively 141,152,158,223,248,115 ng/mL, and is approaching with embodiment 1 mensuration result; The moving phase combination of adopting present embodiment is described, can be realized the accurate mensuration of methyl amimoacetic acid equally.
Embodiment 4
Change mobile phase A among the embodiment 1 into contain modifier 0.2% formic acid and 5mmol/L ammonium formate the WS, Mobile phase B is an acetonitrile, gradient elution.Elution program is: 0～1 min, and the Mobile phase B volume accounts for 30% of cumulative volume; 1～2min, Mobile phase B accounts for 70%; 2～3min, Mobile phase B accounts for 90%; 3～6min, Mobile phase B changes into again and accounts for 30%.Flow velocity 0.3mL/min; Sample size 5 μ L, other measures methyl amimoacetic acid concentration in 6 parts of urine samples equally with embodiment 1 operation; Be respectively 133,142,147,210,241,109 ng/mL; Approaching with embodiment 1 mensuration result, the moving phase combination of adopting present embodiment is described, can realize the accurate mensuration of methyl amimoacetic acid equally.
Embodiment 5
Methyl amimoacetic acid assay method in the urine sample is carried out the methodology checking.The withinrun precision of methyl amimoacetic acid (in relative standard deviation) is less than 12% in the urine sample, and accuracy is 87.8%～99.5%.Betweenrun precision (in relative standard deviation) is less than 10%, and accuracy is 91.4%～97.4%.Stability test is the result show, placed 48 hours through pretreated urine sample to be measured (4 ℃) in automatic sampler, the urine sample room temperature place 24 hours, through 3 freeze thawing all keep stablizing, urine sample-20 ℃ frozen 49 days, all keep stable.
1. typical curve and quantitatively scope
Press embodiment 1 method preparation methyl amimoacetic acid typical curve, divide 3 batches, the parallel appearance of each concentration preparation 2 times, sample introduction analysis.With methyl amimoacetic acid concentration is the x axle, and methyl amimoacetic acid is the Y axle with the ratio of interior mark peak area, carries out linear regression, sets up regression equation.Visible by Fig. 1 result, methyl amimoacetic acid has the favorable linearity correlativity.Minimum 100 ng/mL that quantitatively are limited to of this law methyl amimoacetic acid.
2. accuracy and precision
Press the quality-control sample of embodiment 1 method preparation methyl amimoacetic acid.Every kind of concentration is prepared 6 parts, on the same day, handles and analyzes by above-mentioned sample treatment and check and analysis condition, calculates withinrun precision and accuracy.As stated above, divide 3 days preparation 3 lot sample article to handle and analyze, calculate betweenrun precision and accuracy, the result sees table 1.
3. the recovery
Sample concentration, disposal route and sampling condition are all measured item down with precision and correctness, and the recovery that records is 85.9%～90.5%.
4. stable
Sample concentration, disposal route and sampling condition are all with under precision and the accuracy determination item; Investigate in the automatic sampler 48 hours, freeze thawing 3 times, room temperature place 24 hours ,-20 ℃ and placed 49 days; Stability test is the result show; Place 48h through the methyl amimoacetic acid of pretreated urine sample to be measured and chemical example in automatic sampler (4 ℃), the urine sample room temperature place 24h, through 3 freeze thawing all keep stablizing, urine sample-20 ℃ frozen 49d, all keep stable.
Minimum 100 ng/mL that quantitatively are limited to of methyl amimoacetic acid in the urine sample, in the 100-5000 ng/mL concentration range, linearly dependent coefficient is greater than 0.99, and accuracy is between 87.8%～99.5%, in batch, betweenrun precision is all less than 12%.This method can be distinguished the chaff interference of similar in the sample, and sample directly detects after diluting, and aspect specificity, have clear superiority, and reagent cost is cheap, is applicable to the detection requirement of clinical great amount of samples.
Claims (2)
1. the quantitative detecting method of methyl amimoacetic acid in the urine sample is characterized in that:
(1) urine sample dilution in acetonitrile: get 100 μ L urine samples at random, adding 20 μ L concentration is mark working fluid in 50 μ g/mL methyl amimoacetic acid-d3, adds 200 μ L acetonitriles; DL 30s; Centrifugal 3 min of 15000 rpm abandon deposition, draw 100 μ L supernatants and mix with 300 μ L acetonitriles; Be transferred to the sample introduction bottle, supply analytical test;
(2) chromatographic resolution: with silica gel bonded phase filling is analytical column; With the WS is mobile phase A; Acetonitrile solution is a Mobile phase B, and said A contains 0.02～0.4% formic acid and 1～5mmol/L ammonium formate in mutually as modifier, and flow velocity is 0.1～1 mL/min; Isocratic elution or gradient elution are with methyl amimoacetic acid wash-out from the analytical column;
(3) Mass Spectrometer Method: adopt the electric spray ion source tandem mass spectrometer, under the positive ion detecting pattern, the multiple-reaction monitoring scanning analysis detects methyl amimoacetic acid;
(4) result calculates: with methyl amimoacetic acid peak area or the peak heights that Mass Spectrometer Method obtains, press the isotopic dilution internal standard method and calculate the content of methyl amimoacetic acid in urine sample.
2. according to the quantitative detecting method of methyl amimoacetic acid in the said urine sample of claim 1; It is characterized in that: said step (3) Mass Spectrometer Method source parameters is set to methyl amimoacetic acid sense channel m/z 90/44; Methyl amimoacetic acid-d3 sense channel m/z 93/47, the ion channel scope is ± 0.5 m/z.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101545904A CN102662013A (en) | 2012-05-18 | 2012-05-18 | Quantitative detection method of sarcosine in urine sample |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101545904A CN102662013A (en) | 2012-05-18 | 2012-05-18 | Quantitative detection method of sarcosine in urine sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102662013A true CN102662013A (en) | 2012-09-12 |
Family
ID=46771545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101545904A Pending CN102662013A (en) | 2012-05-18 | 2012-05-18 | Quantitative detection method of sarcosine in urine sample |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102662013A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3404418A2 (en) | 2017-05-16 | 2018-11-21 | Prevention Medicals s.r.o. | A diagnostic strip for determining the amount of sarcosine, creatinine and hydrogen peroxide in a biological or environmental sample |
| CN112162049A (en) * | 2020-10-13 | 2021-01-01 | 合肥谱佳医学检验实验室有限公司 | Method for detecting sarcosine in urine for non-diagnosis purpose |
| CN115144517A (en) * | 2022-05-31 | 2022-10-04 | 北京豪思生物科技股份有限公司 | Method for detecting sarcosine and metabolites thereof in sample, kit and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1750126A1 (en) * | 2004-05-26 | 2007-02-07 | Ajinomoto Co., Inc. | Method and apparatus for analyzing aminofunctional compound |
| CN101718746A (en) * | 2009-12-30 | 2010-06-02 | 中国科学院长春应用化学研究所 | Method for detecting sarcosine |
| US20100140467A1 (en) * | 2004-10-12 | 2010-06-10 | Scott Goldman | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
| CN102213703A (en) * | 2011-04-11 | 2011-10-12 | 中南大学 | Method for measuring contents of tyrosine, tryptophan and 5-hydroxytryptamine in blood serum by high-efficiency liquid phase chromatography-fluorescence method |
| JP2011247869A (en) * | 2010-04-27 | 2011-12-08 | Kobe Univ | Inspection method of specific disease using metabolome analysis method |
| CN102288704A (en) * | 2011-08-10 | 2011-12-21 | 河北神威药业有限公司 | Method for quantitatively detecting Qingkailing injection |
-
2012
- 2012-05-18 CN CN2012101545904A patent/CN102662013A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1750126A1 (en) * | 2004-05-26 | 2007-02-07 | Ajinomoto Co., Inc. | Method and apparatus for analyzing aminofunctional compound |
| US20100140467A1 (en) * | 2004-10-12 | 2010-06-10 | Scott Goldman | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
| CN101718746A (en) * | 2009-12-30 | 2010-06-02 | 中国科学院长春应用化学研究所 | Method for detecting sarcosine |
| JP2011247869A (en) * | 2010-04-27 | 2011-12-08 | Kobe Univ | Inspection method of specific disease using metabolome analysis method |
| CN102213703A (en) * | 2011-04-11 | 2011-10-12 | 中南大学 | Method for measuring contents of tyrosine, tryptophan and 5-hydroxytryptamine in blood serum by high-efficiency liquid phase chromatography-fluorescence method |
| CN102288704A (en) * | 2011-08-10 | 2011-12-21 | 河北神威药业有限公司 | Method for quantitatively detecting Qingkailing injection |
Non-Patent Citations (6)
| Title |
|---|
| BRUNELLA CAVALIERE ET AL: "Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》, vol. 400, no. 9, 31 July 2011 (2011-07-31) * |
| YONGBING SUN ET AL: "Rapid and sensitive hydrophilic interaction chromatography/tandem mass spectrometry method for the determination of glycyl-sarcosine in cell homogenates", 《JOURNAL OF CHROMATOGRAPHY B》, vol. 877, no. 7, 1 March 2009 (2009-03-01) * |
| YONGQING JIANG ET AL: "Quantitative Determination of Sarcosine and Related Compounds in Urinary Samples by Liquid Chromatography with Tandem Mass Spectrometry", 《ANALYTICAL CHEMISTRY》, vol. 82, no. 21, 1 November 2010 (2010-11-01) * |
| 何智慧等: "基于HPLC-MS的健康吸烟人群代谢组学研究", 《化学研究与应用》, vol. 22, no. 6, 30 June 2010 (2010-06-30) * |
| 刘俊英等: "同位素内标法测定欧李果原汁氨基酸", 《食品研究与开发》, vol. 31, no. 8, 31 August 2010 (2010-08-31) * |
| 危晴等: "同位素内标法测定欧李果汁游离氨基酸及成分分析", 《食品科技》, vol. 36, no. 10, 31 October 2011 (2011-10-31) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3404418A2 (en) | 2017-05-16 | 2018-11-21 | Prevention Medicals s.r.o. | A diagnostic strip for determining the amount of sarcosine, creatinine and hydrogen peroxide in a biological or environmental sample |
| CN112162049A (en) * | 2020-10-13 | 2021-01-01 | 合肥谱佳医学检验实验室有限公司 | Method for detecting sarcosine in urine for non-diagnosis purpose |
| CN115144517A (en) * | 2022-05-31 | 2022-10-04 | 北京豪思生物科技股份有限公司 | Method for detecting sarcosine and metabolites thereof in sample, kit and application thereof |
| CN115144517B (en) * | 2022-05-31 | 2023-07-21 | 北京豪思生物科技股份有限公司 | Method for detecting sarcosine and metabolite thereof in sample, and kit and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization | |
| CN101876650B (en) | Method for measuring formaldehyde content in smoke aqueous gel | |
| CN103822998A (en) | Method for analyzing amine substances in dansyl chloride derived-plasma based on liquid chromatography mass spectrometry | |
| CN114373510B (en) | Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof | |
| EP3521818B1 (en) | Device for diagnosing colorectal cancer and method for providing colorectal cancer diagnosis information | |
| CN104020241A (en) | Synchronous analysis method for trace nicotine in blood-brain samples of animal and main metabolites thereof | |
| CN112162050B (en) | Application of MIT and/or DIT as thyroid cancer marker and kit | |
| CN111896641B (en) | Colorectal cancer related estrogen plasma metabolism small molecule screening method and application thereof | |
| CN108802240A (en) | The extraction of cannabinoid compound and detection method in hair | |
| CN102662013A (en) | Quantitative detection method of sarcosine in urine sample | |
| CN102426210A (en) | Detection method of polyamine substances in blood plasma | |
| Kałużna-Czaplińska et al. | Current applications of chromatographic methods for diagnosis and identification of potential biomarkers in cancer | |
| CN117368476B (en) | Application of detection reagent for seven metabolic markers in preparation of breast cancer diagnosis and prognosis products | |
| US20130102011A1 (en) | Human leucine-rich a-2-glycoprotein-1 and aminopeptidase n as risk indicators for cancer | |
| Bakry et al. | Recent advances in capillary electrophoresis for biomarker discovery | |
| CN112986441A (en) | Tumor marker screened from tissue metabolism contour, application thereof and auxiliary diagnosis method | |
| CN101246176B (en) | Mass spectrum kit for detecting squamous-cell carcinoma antigen feminine cervical carcinoma serum protein and preparation method thereof | |
| CN109444287B (en) | LC-MS/MS quantitative detection method for alpha fetoprotein | |
| CN110261518A (en) | A kind of screening of human body effect of low dose radiation molecular injury marker taurine and verification method | |
| CN107085064B (en) | The high performance liquid chromatography-tandem mass Simultaneous Detection of acetic acid fusarinine C and double methyl mercapto gliotoxins in sputum | |
| CN102324001A (en) | Method for predicting gastric cancer on the basis of high performance liquid chromatography/mass spectrometry (HPLC/MS) metabonomics data analysis | |
| CN111426760B (en) | Method for determining genotoxic impurities in doxofylline raw material medicine | |
| CN101206203B (en) | Method for detecting urine metabolite based on deriving method | |
| CN113917008A (en) | Application of product for detecting metabolite level in urine by mass spectrometry in preparation of product for early evaluation of intestinal polyp and colorectal cancer | |
| CN109061179A (en) | Application of the amino acid combined factor in building colorectal cancer hematology diagnostic model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120912 |